TCM
MRNA icon

Traynor Capital Management’s Moderna MRNA Stock Holding History

Traynor Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40,000
Closed -$7.18M – 230
2022
Q4 		$7.18M Buy
+40,000
New +$6.54M 1.01% 23

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Traynor Capital Management's MRNA Position: Q1 2023 in Review

Traynor Capital Management sold out of Moderna (MRNA) in Q1 2023, closing a stake of 323 shares — an estimated $58K sold.

Traynor Capital Management first reported a position in MRNA in Q3 2021 and held it in 3 quarters. The position peaked at $1.49M in Q4 2021. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Traynor Capital Management reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Traynor Capital Management sold 323 Moderna shares in Q1 2023, an estimated $58K.
  • Traynor Capital Management first reported a position in Moderna in Q3 2021 and held it in 3 quarters.
  • Traynor Capital Management's Moderna position peaked at $1.49M in Q4 2021.
  • 1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Traynor Capital Management's 13F filing for Q1 2023, filed 21 Apr 2023.